Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: van Oers, Marinus, Smolej, Lukas, Petrini, Mario, Offner, Fritz, Grosicki, Sebastian, Levin, Mark-David, Davis, Jaclyn, Banerjee, Hiya, Stefanelli, Tommaso, Hoever, Petra, Geisler, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6893027/
https://ncbi.nlm.nih.gov/pubmed/31801940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0260-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados